RSS-Feed abonnieren
DOI: 10.1055/s-0042-1745747
Understanding the Updates in the Asthma Guidelines
![](https://www.thieme-connect.de/media/srccm/202205/lookinside/thumbnails/10-1055-s-0042-1745747_220501-1.jpg)
Abstract
Asthma is a chronic inflammatory lung disease that affects millions of Americans, with variable symptoms of bronchospasm and obstruction among individuals over time. The National Heart, Lung, and Blood Institute (NHLBI) published the 2020 Focused Updates to the Asthma Management Guidelines based on the latest research since the 2007 Expert Panel Report-3 (EPR-3). The following article reviews the 21 new recommendations on the six core topics in asthma: use of intermittent inhaled corticosteroids, long-acting muscarinic antagonist therapy, use of the fractional exhaled nitric oxide test in asthma diagnosis and monitoring, indoor allergen mitigation, immunotherapy, and bronchial thermoplasty. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate recommendations as strong or conditional based on the evidence. The recommendations were based on systematic reviews of the literature and focused on patient-centered critical outcomes of asthma exacerbations, asthma control, and asthma-related quality of life. Understanding the recommendations with consideration of individual values through shared decision-making may improve asthma outcomes.
Publikationsverlauf
Artikel online veröffentlicht:
21. Juni 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 National Center for Health Statistics. Percentage of ever having asthma for adults aged 18 and over, United States, 2019. National Health Interview Survey. 2019.. Accessed September 12, 2021 at: https://www.cdc.gov/NHISDataQueryTool/SHS_2019_ADULT3/index.html
- 2 National Center for Health Statistics. Percentage of ever having asthma for children under age 18 years, United States, 2019. National Health Interview Survey 2019. . Accessed September 21, 2021 at: https://www.cdc.gov/NHISDataQueryTool/SHS_2019_CHILD3/index.html
- 3 National Center for Health Statistics. Health, United States, 2019: Table ##. Hyattsville, MD. 2021. Accessed September 21, 2021 at: https://www.cdc.gov/nchs/hus/contents2019.htm 2019
- 4 National Hospital Ambulatory Medical Care Survey: 2018 emergency department summary tables.. 2018 . Accessed October 7, 2021 at: https://www.cdc.gov/nchs/data/nhamcs/web_tables/2018_ed_web_tables-508.pdf
- 5 Most recent asthma data.. 2021 . Accessed January 16, 2021 at: http://www.cdc.gov/asthma/national-surveillance-data/default.htm
- 6 Leas BF, D'Anci KE, Apter AJ, Bryant-Stephens T, Schoelles K, Umscheid CA. AHRQ Comparative Effectiveness Reviews. Effectiveness of Indoor Allergen Reduction in Management of Asthma.. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018
- 7 Lin SY, Azar A, Suarez-Cuervo C. et al. AHRQ Comparative Effectiveness Reviews. The Role of Immunotherapy in the Treatment of Asthma.. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018
- 8 Wang Z, Pianosi P, Keogh K. et al. AHRQ Comparative Effectiveness Reviews. The Clinical Utility of Fractional Exhaled Nitric Oxide (FENO) in Asthma Management.. Rockville, MD: Agency for Healthcare Research and Quality (US); 2017
- 9 Sobieraj DM, Baker WL, Weeda ER. et al. AHRQ Comparative Effectiveness Reviews. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma.. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018
- 10 Cloutier MM, Baptist AP, Blake KV. et al; Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146 (06) 1217-1270
- 11 Guyatt GH, Oxman AD, Kunz R. et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64 (04) 395-400
- 12 Durham AL, Caramori G, Chung KF, Adcock IM. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res 2016; 167 (01) 192-203
- 13 Reddel HK, Busse WW, Pedersen S. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017; 389 (10065): 157-166
- 14 National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (Suppl. 05) S94-S138
- 15 Bacharier LB, Phillips BR, Zeiger RS. et al; CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122 (06) 1127-1135 .e8
- 16 Ducharme FM, Lemire C, Noya FJ. et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360 (04) 339-353
- 17 Svedmyr J, Nyberg E, Thunqvist P, Asbrink-Nilsson E, Hedlin G. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 1999; 88 (01) 42-47
- 18 Boushey HA, Sorkness CA, King TS. et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352 (15) 1519-1528
- 19 Calhoun WJ, Ameredes BT, King TS. et al; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012; 308 (10) 987-997
- 20 Papi A, Canonica GW, Maestrelli P. et al; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356 (20) 2040-2052
- 21 Martinez FD, Chinchilli VM, Morgan WJ. et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9766): 650-657
- 22 Turpeinen M, Nikander K, Pelkonen AS. et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (the Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93 (08) 654-659
- 23 Camargos P, Affonso A, Calazans G. et al. On-demand intermittent beclomethasone is effective for mild asthma in Brazil. Clin Transl Allergy 2018; 8: 7
- 24 Jackson DJ, Bacharier LB, Mauger DT. et al; National Heart, Lung, and Blood Institute AsthmaNet. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med 2018; 378 (10) 891-901
- 25 Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363 (9405): 271-275
- 26 Lahdensuo A, Haahtela T, Herrala J. et al. Randomised comparison of guided self management and traditional treatment of asthma over one year. BMJ 1996; 312 (7033): 748-752
- 27 Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180 (07) 598-602
- 28 McKeever T, Mortimer K, Wilson A. et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018; 378 (10) 902-910
- 29 O'Byrne PM, Bisgaard H, Godard PP. et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (02) 129-136
- 30 Rabe KF, Pizzichini E, Ställberg B. et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129 (02) 246-256
- 31 Scicchitano R, Aalbers R, Ukena D. et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (09) 1403-1418
- 32 Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130 (06) 1733-1743
- 33 Atienza T, Aquino T, Fernández M. et al. Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results. Respirology 2013; 18 (02) 354-363
- 34 Papi A, Corradi M, Pigeon-Francisco C. et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1 (01) 23-31
- 35 Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368 (9537): 744-753
- 36 Patel M, Pilcher J, Pritchard A. et al; SMART Study Group. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1 (01) 32-42
- 37 Vogelmeier C, D'Urzo A, Pauwels R. et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 2005; 26 (05) 819-828
- 38 Bousquet J, Boulet LP, Peters MJ. et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101 (12) 2437-2446
- 39 Kuna P, Peters MJ, Manjra AI. et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61 (05) 725-736
- 40 Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009; 63 (10) 1479-1488
- 41 Quirce S, Barcina C, Plaza V. et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. J Asthma 2011; 48 (08) 839-847
- 42 Riemersma RA, Postma D, van der Molen T. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J 2012; 21 (01) 50-56
- 43 Sears MR, Boulet LP, Laviolette M. et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008; 31 (05) 982-989
- 44 Wechsler ME, Yawn BP, Fuhlbrigge AL. et al; BELT Investigators. Anticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in black adults with asthma: the BELT randomized clinical trial. JAMA 2015; 314 (16) 1720-1730
- 45 Peters SP, Kunselman SJ, Icitovic N. et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363 (18) 1715-1726
- 46 Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med 2015; 109 (01) 54-62
- 47 Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128 (02) 315-322
- 48 Kerstjens HA, Casale TB, Bleecker ER. et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 2015; 3 (05) 367-376
- 49 Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clin Ther 2014; 36 (04) 526-533
- 50 Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther 2015; 37 (02) 418-426
- 51 Hamelmann E, Bateman ED, Vogelberg C. et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol 2016; 138 (02) 441-450 .e8
- 52 Paggiaro P, Halpin DM, Buhl R. et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract 2016; 4 (01) 104-13 .e2
- 53 Dweik RA, Boggs PB, Erzurum SC. et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184 (05) 602-615
- 54 Szefler SJ, Mitchell H, Sorkness CA. et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372 (9643): 1065-1072
- 55 de Jongste JC, Carraro S, Hop WC, Baraldi E. CHARISM Study Group. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179 (02) 93-97
- 56 Fritsch M, Uxa S, Horak Jr F. et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatr Pulmonol 2006; 41 (09) 855-862
- 57 Peirsman EJ, Carvelli TJ, Hage PY. et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol 2014; 49 (07) 624-631
- 58 Petsky HL, Li AM, Au CT, Kynaston JA, Turner C, Chang AB. Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatr Pulmonol 2015; 50 (06) 535-543
- 59 Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172 (07) 831-836
- 60 Pike K, Selby A, Price S. et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clin Respir J 2013; 7 (02) 204-213
- 61 Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ. et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax 2015; 70 (06) 543-550
- 62 Verini M, Consilvio NP, Di Pillo S. et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. J Allergy (Cairo) 2010; 2010: 691425
- 63 Zeiger RS, Szefler SJ, Phillips BR. et al; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117 (01) 45-52
- 64 Visitsunthorn N, Mahawichit N, Maneechotesuwan K. Association between levels of fractional exhaled nitric oxide and asthma exacerbations in Thai children. Respirology 2017; 22 (01) 71-77
- 65 van Vliet D, Alonso A, Rijkers G. et al. Prediction of asthma exacerbations in children by innovative exhaled inflammatory markers: results of a longitudinal study. PLoS One 2015; 10 (03) e0119434
- 66 McCormack MC, Aloe C, Curtin-Brosnan J, Diette GB, Breysse PN, Matsui EC. Guideline-recommended fractional exhaled nitric oxide is a poor predictor of health-care use among inner-city children and adolescents receiving usual asthma care. Chest 2013; 144 (03) 923-929
- 67 Raj D, Lodha R, Mukherjee A, Sethi T, Agrawal A, Kabra SK. Fractional exhaled nitric oxide in children with acute exacerbation of asthma. Indian Pediatr 2014; 51 (02) 105-111
- 68 Salmeron S, Liard R, Elkharrat D, Muir J, Neukirch F, Ellrodt A. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet 2001; 358 (9282): 629-635
- 69 Gill M, Walker S, Khan A. et al. Exhaled nitric oxide levels during acute asthma exacerbation. Acad Emerg Med 2005; 12 (07) 579-586
- 70 Ko FW, Hui DS, Leung TF. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology 2012; 17 (02) 370-378
- 71 Zeiger RS, Schatz M, Zhang F. et al. Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids. J Asthma 2011; 48 (01) 8-17
- 72 Balinotti JE, Colom A, Kofman C, Teper A. Association between the Asthma Predictive Index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing. Arch Argent Pediatr 2013; 111 (03) 191-195
- 73 Bloemen K, Van Den Heuvel R, Govarts E. et al. A new approach to study exhaled proteins as potential biomarkers for asthma. Clin Exp Allergy 2011; 41 (03) 346-356
- 74 Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162 (4 Pt 1): 1403-1406
- 75 Caudri D, Wijga AH, Hoekstra MO. et al. Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE. Thorax 2010; 65 (09) 801-807
- 76 Chang D, Yao W, Tiller CJ. et al. Exhaled nitric oxide during infancy as a risk factor for asthma and airway hyperreactivity. Eur Respir J 2015; 45 (01) 98-106
- 77 Elliott M, Heltshe SL, Stamey DC, Cochrane ES, Redding GJ, Debley JS. Exhaled nitric oxide predicts persistence of wheezing, exacerbations, and decline in lung function in wheezy infants and toddlers. Clin Exp Allergy 2013; 43 (12) 1351-1361
- 78 Klaassen EM, van de Kant KD, Jöbsis Q. et al. Symptoms, but not a biomarker response to inhaled corticosteroids, predict asthma in preschool children with recurrent wheeze. Mediators Inflamm 2012; 2012: 162571
- 79 Prado CM, Martins MA, Tibério IF. Nitric oxide in asthma physiopathology. ISRN Allergy 2011; 2011: 832560
- 80 Singer F, Luchsinger I, Inci D. et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy 2013; 68 (04) 531-538
- 81 van Wonderen KE, van der Mark LB, Mohrs J. et al. Prediction and treatment of asthma in preschool children at risk: study design and baseline data of a prospective cohort study in general practice (ARCADE). BMC Pulm Med 2009; 9: 13
- 82 Carswell F, Birmingham K, Oliver J, Crewes A, Weeks J. The respiratory effects of reduction of mite allergen in the bedrooms of asthmatic children—a double-blind controlled trial. Clin Exp Allergy 1996; 26 (04) 386-396
- 83 Cloosterman SG, Schermer TR, Bijl-Hofland ID. et al. Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clin Exp Allergy 1999; 29 (10) 1336-1346
- 84 El-Ghitany EM, Abd El-Salam MM. Environmental intervention for house dust mite control in childhood bronchial asthma. Environ Health Prev Med 2012; 17 (05) 377-384
- 85 Marks GB, Tovey ER, Green W, Shearer M, Salome CM, Woolcock AJ. House dust mite allergen avoidance: a randomized controlled trial of surface chemical treatment and encasement of bedding. Clin Exp Allergy 1994; 24 (11) 1078-1083
- 86 Shapiro GG, Wighton TG, Chinn T. et al. House dust mite avoidance for children with asthma in homes of low-income families. J Allergy Clin Immunol 1999; 103 (06) 1069-1074
- 87 DiMango E, Serebrisky D, Narula S. et al. Individualized household allergen intervention lowers allergen level but not asthma medication use: a randomized controlled trial. J Allergy Clin Immunol Pract 2016; 4 (04) 671-679 .e4
- 88 Krieger J, Takaro TK, Song L, Beaudet N, Edwards K. A randomized controlled trial of asthma self-management support comparing clinic-based nurses and in-home community health workers: the Seattle-King County Healthy Homes II Project. Arch Pediatr Adolesc Med 2009; 163 (02) 141-149
- 89 Krieger JW, Takaro TK, Song L, Weaver M. The Seattle-King County Healthy Homes Project: a randomized, controlled trial of a community health worker intervention to decrease exposure to indoor asthma triggers. Am J Public Health 2005; 95 (04) 652-659
- 90 Warner JA, Frederick JM, Bryant TN. et al. Mechanical ventilation and high-efficiency vacuum cleaning: a combined strategy of mite and mite allergen reduction in the control of mite-sensitive asthma. J Allergy Clin Immunol 2000; 105 (1 Pt 1): 75-82
- 91 Morgan WJ, Crain EF, Gruchalla RS. et al; Inner-City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351 (11) 1068-1080
- 92 Parker EA, Israel BA, Robins TG. et al. Evaluation of community action against asthma: a community health worker intervention to improve children's asthma-related health by reducing household environmental triggers for asthma. Health Educ Behav 2008; 35 (03) 376-395
- 93 Eggleston PA, Butz A, Rand C. et al. Home environmental intervention in inner-city asthma: a randomized controlled clinical trial. Ann Allergy Asthma Immunol 2005; 95 (06) 518-524
- 94 Matsui EC, Perzanowski M, Peng RD. et al. Effect of an integrated pest management intervention on asthma symptoms among mouse-sensitized children and adolescents with asthma: a randomized clinical trial. JAMA 2017; 317 (10) 1027-1036
- 95 Evans III R, Gergen PJ, Mitchell H. et al. A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. J Pediatr 1999; 135 (03) 332-338
- 96 Bryant-Stephens T, Kurian C, Guo R, Zhao H. Impact of a household environmental intervention delivered by lay health workers on asthma symptom control in urban, disadvantaged children with asthma. Am J Public Health 2009; 99 (Suppl. 03) S657-S665
- 97 Bryant-Stephens T, Li Y. Outcomes of a home-based environmental remediation for urban children with asthma. J Natl Med Assoc 2008; 100 (03) 306-316
- 98 Burr ML, Matthews IP, Arthur RA. et al. Effects on patients with asthma of eradicating visible indoor mould: a randomised controlled trial. Thorax 2007; 62 (09) 767-772
- 99 Williams SG, Brown CM, Falter KH. et al. Does a multifaceted environmental intervention alter the impact of asthma on inner-city children?. J Natl Med Assoc 2006; 98 (02) 249-260
- 100 Rabito FA, Carlson JC, He H, Werthmann D, Schal C. A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children. J Allergy Clin Immunol 2017; 140 (02) 565-570
- 101 Levy JI, Brugge D, Peters JL, Clougherty JE, Saddler SS. A community-based participatory research study of multifaceted in-home environmental interventions for pediatric asthmatics in public housing. Soc Sci Med 2006; 63 (08) 2191-2203
- 102 Powell H, Murphy VE, Taylor DR. et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378 (9795): 983-990
- 103 Gallego MT, Iraola V, Himly M. et al. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response. Int Arch Allergy Immunol 2010; 153 (01) 61-69
- 104 García-Robaina JC, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118 (05) 1026-1032
- 105 Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52 (08) 853-859
- 106 Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI subcutaneous immunotherapy surveillance study (2013-2017): fatalities, infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract 2019; 7 (06) 1996-2003 .e1
- 107 Lieberman P. The risk and management of anaphylaxis in the setting of immunotherapy. Am J Rhinol Allergy 2012; 26 (06) 469-474
- 108 Gómez Vera J, Flores Sandoval G, Orea Solano M, López Tiro J, Jiménez Saab N. [Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus]. Rev Alerg Mex 2005; 52 (06) 231-236
- 109 Virchow JC, Backer V, Kuna P. et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA 2016; 315 (16) 1715-1725
- 110 de Blay F, Kuna P, Prieto L. et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma–post hoc results from a randomised trial. Respir Med 2014; 108 (10) 1430-1437
- 111 Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy 2016; 71 (02) 249-257
- 112 Marogna M, Braidi C, Bruno ME. et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr) 2013; 41 (04) 216-224
- 113 Mosbech H, Canonica GW, Backer V. et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol 2015; 114 (02) 134-140
- 114 Wang L, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014; 69 (09) 1181-1188
- 115 Maloney J, Prenner BM, Bernstein DI. et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol 2016; 116 (01) 59-65
- 116 Mösges R, Graute V, Christ H, Sieber HJ, Wahn U, Niggemann B. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol 2010; 21 (08) 1135-1138
- 117 Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18 (01) 47-57
- 118 Shao J, Cui YX, Zheng YF. et al. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy 2014; 28 (02) 131-139
- 119 Cox G, Thomson NC, Rubin AS. et al; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356 (13) 1327-1337
- 120 Pavord ID, Cox G, Thomson NC. et al; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176 (12) 1185-1191
- 121 Balu A, Ryan D, Niven R. Lung abscess as a complication of bronchial thermoplasty. J Asthma 2015; 52 (07) 740-742
- 122 Facciolongo N, Menzella F, Lusuardi M. et al. Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report. Multidiscip Respir Med 2015; 10 (01) 9
- 123 Nguyen DV, Murin S. Bronchial artery pseudoaneurysm with major hemorrhage after bronchial thermoplasty. Chest 2016; 149 (04) e95-e97
- 124 Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006; 173 (09) 965-969
- 125 Doeing DC, Husain AN, Naureckas ET, White SR, Hogarth DK. Bronchial thermoplasty failure in severe persistent asthma: a case report. J Asthma 2013; 50 (07) 799-801
- 126 Doeing DC, Mahajan AK, White SR, Naureckas ET, Krishnan JA, Hogarth DK. Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series. J Asthma 2013; 50 (02) 215-218
- 127 Funatsu A, Kobayashi K, Iikura M, Ishii S, Izumi S, Sugiyama H. A case of pulmonary cyst and pneumothorax after bronchial thermoplasty. Respirol Case Rep 2017; 6 (02) e00286
- 128 Han X, Zhang S, Zhao W. et al. A successful bronchial thermoplasty procedure in a “very severe” asthma patient with rare complications: a case report. J Asthma 2019; 56 (09) 1004-1007
- 129 Mahajan AK, Hogarth DK. Bronchial thermoplasty: therapeutic success in severe asthma associated with persistent airflow obstruction. J Asthma 2012; 49 (05) 527-529
- 130 Menzella F, Lusuardi M, Galeone C, Montanari G, Cavazza A, Facciolongo N. Heat-induced necrosis after bronchial thermoplasty: a new concern?. Allergy Asthma Clin Immunol 2018; 14: 25
- 131 Qiu M, Lai Z, Wei S. et al. Bronchiectasis after bronchial thermoplasty. J Thorac Dis 2018; 10 (10) E721-E726
- 132 Takeuchi A, Kanemitsu Y, Takakuwa O. et al. A suspected case of inflammatory bronchial polyp induced by bronchial thermoplasty but resolved spontaneously. J Thorac Dis 2018; 10 (09) E678-E681
- 133 Lieu TA, Au D, Krishnan JA. et al; Comparative Effectiveness Research in Lung Diseases Workshop Panel. Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop. Am J Respir Crit Care Med 2011; 184 (07) 848-856